Page 2 - Scientific Library

In March 2016, Mark J Osborn et al published in Molecular Therapy a major article for genome editing (doi:10.1038/mt.2015.197), about knock-out of CD3 in human T-cells. The goal is to improve T-cell-based

Sequence engineering and chemical modification of CAS9 mRNA

For transgenesis and

Vector-free CRISPR-CAS9 gene editing to accelerate therapeutic applications

A few years ago, Ayal Hendel et al (doi:10.1038/nbt.3290) published results revealing that chemical alterations to sgRNA enhance

Cell-based assays have become a classic way to monitor cells' reactions to a treatment or a specific stimulus. They involve a reporter construction and a detection system. The classic system is Firefly

Cell-based assays, screening for pathway activation or inhibition are classically done with promoter reporter clones expressing Firefly luciferase. Brighter, more stable, more sensitive, more convenient

RNA-based CRISPR-CAS9 gene editing is a vector-free approach that is required for therapeutic perspectives. However, from a practical point of view, what appears as a major challenge to engineer primary

Optimal knock-down can be done by a shRNA sequence that depends on the gene expression level and the cell type. Usually, 4 shRNA should be tested to find the one inducing a minimum of 70% increase of the

Recent articles have highlighted the role the STING cell signalling pathway may be playing in drug development, whether via its inhibition to control innate immunity and inflammation (Nature Biotechnology,